Literature DB >> 9393291

Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' Study. International Continence Society--Benign Prostatic Hyperplasia.

J L Donovan1, H E Kay, T J Peters, P Abrams, J Coast, A Matos-Ferreira, L Rentzhog, J L Bosch, J Nordling, J B Gajewski, G Barbalias, E Schick, M M Silva, I Nissenkorn, J J de la Rosette.   

Abstract

OBJECTIVE: To present and describe the validity and reliability of the International Continence Society-Benign Prostatic Hyperplasia study quality-of-life (ICSQoL) instrument, a new set of questions to assess the impact of lower urinary tract symptoms (LUTS) on quality of life (QoL) in middle-aged and elderly men. PATIENTS AND METHODS: The study comprised 1271 consecutive men over the age of 45 years, attending urology departments in 12 countries, with LUTS and possible benign prostatic obstruction who were recruited to the ICS-'BPH' study (the clinic group); 423 ambulant men were recruited from a general practice in the UK to provide a community group. Each individual completed the ICS-'BPH' study questionnaire which includes six items addressing general and specific aspects of QoL (the ICSQoL). Content and construct validity were assessed by interviews with patients and by testing hypotheses within the study groups, e.g. the relationships with age, individual LUTS (as measured on the ICSmale questionnaire) and generic health status, as measured by the Short Form (SF-36) and EuroQol instruments. Reliability was assessed by measures of internal consistency and a test-retest analysis.
RESULTS: The ICSQoL items were easily understood by patients, were completed with low levels of missing data, and address some (but not all) concerns about the impact of LUTS on QoL. The ICSQoL items have good construct validity, showing expected differences between community and clinic samples, and expected relationships with each other and individual LUTS. Items had good test-retest reliability, but their internal consistency was poor, confirming that ICSQoL questions should not be combined into a score. General ICSQoL items were closely related with most domains of the SF-36 and the EuroQol.
CONCLUSION: ICSQoL items may be used individually or as a group in research studies or in clinical practice.

Entities:  

Mesh:

Year:  1997        PMID: 9393291

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  15 in total

Review 1.  Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life.

Authors:  Donald MacDonald; Thomas A McNicholas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  How important are men's lower urinary tract symptoms (LUTS) and their impact on the quality of life (QOL)?

Authors:  J Haltbakk; B R Hanestad; S Hunskaar
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

3.  Continence specialists use of quality of life information in routine practice: a national survey of practitioners.

Authors:  Kirstie L Haywood; Andrew M Garratt; Sandra Carrivick; Joanne Mangnall; Suzanne M Skevington
Journal:  Qual Life Res       Date:  2009-03-07       Impact factor: 4.147

4.  Self-management for men with lower urinary tract symptoms.

Authors:  Christian T Brown; Mark Emberton
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

5.  Prevalence and impact of pelvic floor dysfunction in an adult cystic fibrosis population: a questionnaire survey.

Authors:  Rebecca Chambers; Adam Lucht; Aisling Reihill; Judith Hough
Journal:  Int Urogynecol J       Date:  2016-10-13       Impact factor: 2.894

Review 6.  Self-management in lower urinary tract symptoms: the next major therapeutic revolution.

Authors:  T L Yap; C T Brown; M Emberton
Journal:  World J Urol       Date:  2006-05-10       Impact factor: 4.226

7.  Adenovirus-mediated delivery of shRNA against bFGF mRNA suppresses growth of cultured human primary prostatic stromal cells.

Authors:  Kai Wang; Linfeng Cheng; Yinghong Liang; Donghui Liu; Kai Li; Ping Wang
Journal:  Mol Biol Rep       Date:  2010-06-06       Impact factor: 2.316

Review 8.  Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.

Authors:  J E Batista-Miranda; M D Diez; P A Bertrán; H Villavicencio
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

9.  Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project.

Authors:  Jordi Alonso; Montserrat Ferrer; Barbara Gandek; John E Ware; Neil K Aaronson; Paola Mosconi; Niels K Rasmussen; Monika Bullinger; Shunichi Fukuhara; Stein Kaasa; Alain Leplège
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

10.  EuroQol EQ-5D and condition-specific measures of health outcome in women with urinary incontinence: reliability, validity and responsiveness.

Authors:  Kirstie L Haywood; Andrew M Garratt; Ranjit Lall; Jan Fereday Smith; Sarah E Lamb
Journal:  Qual Life Res       Date:  2008-02-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.